JPH09505806A - Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用 - Google Patents

Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用

Info

Publication number
JPH09505806A
JPH09505806A JP7512014A JP51201495A JPH09505806A JP H09505806 A JPH09505806 A JP H09505806A JP 7512014 A JP7512014 A JP 7512014A JP 51201495 A JP51201495 A JP 51201495A JP H09505806 A JPH09505806 A JP H09505806A
Authority
JP
Japan
Prior art keywords
aminoindan
salt
propargyl
pai
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP7512014A
Other languages
English (en)
Japanese (ja)
Inventor
ユーディム、マウサ・ビー・エイチ
フィンバーグ、ジョン・ピー・エム
レビイ、ルス
スターリング、ジェフリー
ラーナー、デイビッド
− パスキン、ターツア バーガー
イエリン、ハイム
ベインバーグ、アレックス
Original Assignee
テバ・ファーマシューティカル・インダストリーズ・リミテッド
テクニオン・リサーチ・アンド・デベロップメント・ファウンデーション・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ・ファーマシューティカル・インダストリーズ・リミテッド, テクニオン・リサーチ・アンド・デベロップメント・ファウンデーション・リミテッド filed Critical テバ・ファーマシューティカル・インダストリーズ・リミテッド
Publication of JPH09505806A publication Critical patent/JPH09505806A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
JP7512014A 1993-10-18 1994-10-12 Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用 Withdrawn JPH09505806A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13951793A 1993-10-18 1993-10-18
US08/139,517 1993-10-18
PCT/US1994/011567 WO1995011016A1 (en) 1993-10-18 1994-10-12 R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2002303097A Division JP2003160481A (ja) 1993-10-18 2002-10-17 Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用

Publications (1)

Publication Number Publication Date
JPH09505806A true JPH09505806A (ja) 1997-06-10

Family

ID=22487049

Family Applications (3)

Application Number Title Priority Date Filing Date
JP7512014A Withdrawn JPH09505806A (ja) 1993-10-18 1994-10-12 Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用
JP2002303097A Withdrawn JP2003160481A (ja) 1993-10-18 2002-10-17 Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用
JP2009219662A Pending JP2010018626A (ja) 1993-10-18 2009-09-24 Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2002303097A Withdrawn JP2003160481A (ja) 1993-10-18 2002-10-17 Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用
JP2009219662A Pending JP2010018626A (ja) 1993-10-18 2009-09-24 Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用

Country Status (17)

Country Link
EP (1) EP0812190B1 (enExample)
JP (3) JPH09505806A (enExample)
AT (1) ATE284208T1 (enExample)
AU (1) AU1253495A (enExample)
CA (1) CA2174449C (enExample)
DE (2) DE69434178T2 (enExample)
DK (1) DK0812190T3 (enExample)
ES (1) ES2235170T3 (enExample)
FR (1) FR05C0033I2 (enExample)
HU (1) HU226138B1 (enExample)
IL (1) IL111240A (enExample)
LU (1) LU91191I2 (enExample)
MX (1) MXPA94008019A (enExample)
NL (1) NL300205I2 (enExample)
PT (1) PT812190E (enExample)
WO (1) WO1995011016A1 (enExample)
ZA (1) ZA948013B (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521402A (ja) * 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
JP2009527574A (ja) * 2006-02-21 2009-07-30 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
JP2009534312A (ja) * 2006-04-03 2009-09-24 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
JP2010538067A (ja) * 2007-09-05 2010-12-09 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンを使用する緑内障の治療方法
JP2011507939A (ja) * 2007-12-24 2011-03-10 シプラ・リミテッド プロパルギル化アミノインダン誘導体の合成方法
JP2011522023A (ja) * 2008-06-02 2011-07-28 ジェネリクス・（ユーケー）・リミテッド 鏡像異性的に純粋なアミンの調製方法
JP2011522025A (ja) * 2008-06-02 2011-07-28 ジェネリクス・（ユーケー）・リミテッド アミンの改良調製方法
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
JP2013139452A (ja) * 2005-02-23 2013-07-18 Teva Pharmaceutical Industries Ltd 内容物均一性が改善されたラサギリン製剤
JP2014534196A (ja) * 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
WO1995018617A1 (en) * 1994-01-10 1995-07-13 Teva Pharmaceutical Industries Ltd. 1-aminoindan derivatives and compositions thereof
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
EP0808160A1 (en) * 1995-02-10 1997-11-26 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
PT814789E (pt) * 1995-03-02 2003-09-30 Scherer Technologies Inc R P Composicoes farmaceuticas compreendendo inibidores de monoamina-oxidase b
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
ATE292619T1 (de) 1996-12-18 2005-04-15 Teva Pharma Aminoindanderivate
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
WO1999037293A2 (en) * 1998-01-27 1999-07-29 Thomas Thomas N Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
AU775885B2 (en) 1999-10-27 2004-08-19 Teva Pharmaceutical Industries Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
ES2588780T3 (es) * 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CN101325871B (zh) 2005-12-09 2013-04-10 耶路撒冷希伯来大学伊森姆研究发展公司 低剂量Ladostigil用于神经保护的用途
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
DK2101569T3 (da) 2006-12-14 2012-01-30 Teva Pharma Krystallinsk fast rasagilinbase
BRPI0718339A2 (pt) 2006-12-14 2014-02-18 Teva Pharma Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
US20110117200A1 (en) * 2008-03-31 2011-05-19 Actavis Group Ptc Ehf Rasagiline mesylate particles and process for the preparation thereof
WO2009141737A2 (en) 2008-05-23 2009-11-26 Medichem, S.A. A new method for obtaining an aminoindan mesylate derivative
US20100010098A1 (en) 2008-07-11 2010-01-14 Walter Elffrink Polymorphs of rasagiline hydrochloride
US20100041920A1 (en) * 2008-07-18 2010-02-18 Stephen Benedict David Winter New salt forms of an aminoindan derivative
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
CN102048717B (zh) † 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
WO2011087791A1 (en) 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
WO2011080589A2 (en) * 2009-12-30 2011-07-07 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
EP3517103A1 (en) * 2010-02-03 2019-07-31 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
WO2011121607A2 (en) 2010-03-29 2011-10-06 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
EP2389927A1 (en) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of rasagiline
CN102464589A (zh) * 2010-11-17 2012-05-23 凯瑞斯德生化(苏州)有限公司 雷沙吉兰、其甲磺酸盐及其中间体的制备方法
EP2663545B1 (en) 2011-01-13 2015-07-01 Nobel Ilaç Sanayii Ve Ticaret A.S. A new method for the synthesis of rasagiline
EP2681186B1 (en) 2011-03-03 2016-05-11 Synthon BV Process of resolution of 1-aminoindan
EP2705021A2 (en) 2011-05-04 2014-03-12 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
WO2013139387A1 (en) 2012-03-21 2013-09-26 Synthon Bv Stabilized pharmaceutical compositions comprising rasagiline salts
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
ES2524865T1 (es) 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
ES2502140T1 (es) 2013-02-06 2014-10-02 Galenicum Health S.L. Comprimidos de liberación inmediata de rasagilina hemitartrato
WO2014192022A1 (en) * 2013-05-20 2014-12-04 Cadila Healthcare Limited Pharmaceutical compositions of rasagiline

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013139452A (ja) * 2005-02-23 2013-07-18 Teva Pharmaceutical Industries Ltd 内容物均一性が改善されたラサギリン製剤
JP2009521402A (ja) * 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
JP2014074033A (ja) * 2005-11-17 2014-04-24 Teva Pharmaceutical Industries Ltd プロパルギル化アミノインダンの分離のための方法
JP2009527574A (ja) * 2006-02-21 2009-07-30 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
JP2009534312A (ja) * 2006-04-03 2009-09-24 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
JP2013166772A (ja) * 2006-04-03 2013-08-29 Teva Pharmaceutical Industries Ltd レストレスレッグス症候群の治療のためのラサギリンの使用
JP2010538067A (ja) * 2007-09-05 2010-12-09 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンを使用する緑内障の治療方法
JP2011507939A (ja) * 2007-12-24 2011-03-10 シプラ・リミテッド プロパルギル化アミノインダン誘導体の合成方法
JP2011522025A (ja) * 2008-06-02 2011-07-28 ジェネリクス・（ユーケー）・リミテッド アミンの改良調製方法
JP2011522023A (ja) * 2008-06-02 2011-07-28 ジェネリクス・（ユーケー）・リミテッド 鏡像異性的に純粋なアミンの調製方法
US8569545B2 (en) 2008-06-02 2013-10-29 Generics (Uk) Limited Process for the preparation of enantiomerically pure amines
US8809589B2 (en) 2008-06-02 2014-08-19 Generics [Uk] Limited Process for the preparation of enantiomerically pure amines
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
JP2014534196A (ja) * 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン

Also Published As

Publication number Publication date
EP0812190A4 (en) 1998-03-04
IL111240A0 (en) 1994-12-29
IL111240A (en) 2001-10-31
ZA948013B (en) 1995-05-31
AU1253495A (en) 1995-05-08
DE122005000044I1 (de) 2005-12-22
NL300205I2 (nl) 2006-03-01
ES2235170T3 (es) 2005-07-01
DK0812190T3 (da) 2005-04-11
LU91191I2 (fr) 2005-10-10
NL300205I1 (nl) 2005-10-03
WO1995011016A1 (en) 1995-04-27
JP2010018626A (ja) 2010-01-28
EP0812190B1 (en) 2004-12-08
DE69434178T2 (de) 2005-12-01
DE122005000044I2 (de) 2007-09-13
ATE284208T1 (de) 2004-12-15
FR05C0033I2 (fr) 2006-12-29
DE69434178D1 (de) 2005-01-13
MXPA94008019A (es) 2004-08-10
HU226138B1 (en) 2008-05-28
PT812190E (pt) 2005-04-29
JP2003160481A (ja) 2003-06-03
CA2174449A1 (en) 1995-04-27
CA2174449C (en) 2007-01-16
FR05C0033I1 (enExample) 2005-09-30
HU9601012D0 (en) 1996-06-28
HUT77934A (hu) 1998-11-30
EP0812190A1 (en) 1997-12-17

Similar Documents

Publication Publication Date Title
JPH09505806A (ja) Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用
US5744500A (en) Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5532415A (en) R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060412